Antiviral treatments

1. A method for treating an influenza viral infection in a human comprising administering in multiple intravenous administrations for up to 20 days, the multiple intravenous administrations providing an effective anti-viral amount of from 500 mg to 1,000 mg of a compound of formula I or formula Ia:

or a pharmaceutically acceptable salt thereof, to the human, wherein the influenza viral infection is a seasonal influenza viral infection.

2. The method of claim 1 , wherein the compound of formula I is a compound of formula Ia:

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the effective anti-viral amount is 500 mg.

4. The method of claim 1 , wherein the effective anti-viral amount is 1000 mg.

5. The method of claim 1 , wherein the effective anti-viral amount is 600 mg.

6. The method of claim 1 , further comprising orally administering a neuraminidase inhibitor to the human.

7. The method of claim 6 , wherein the neuraminidase inhibitor that is administered orally is oseltamivir carboxylate.

8. The method of claim 6 , wherein the neuraminidase inhibitor that is administered orally is a compound of formula I, II, III, or IV:

or a pharmaceutically acceptable salt thereof.

9. The method of claim 6 , wherein the neuraminidase inhibitor that is administered orally is a compound of formula Ia, IIa, IIIa, or IVa:

or a pharmaceutically acceptable salt thereof.

10. The method of claim 6 , wherein the neuraminidase inhibitor that is administered orally is a compound of formula Ia,

or a pharmaceutically acceptable salt thereof.

11. The method of claim 6 , wherein the neuraminidase inhibitor that is administered orally is administered for up to 20 days.

12. The method of claim 6 , wherein the neuraminidase inhibitor that is administered orally is administered for up to 10 days.

13. The method of claim 6 , wherein the neuraminidase inhibitor that is administered orally is administered for up to 5 days.